Akribion Therapeutics, a Zwingenberg-based BioTech startup creating a RNA-guided, nuclease-based know-how for programmable cell depletion, right this moment broadcasts its exit from stealth and the completion of a Seed financing spherical elevating €8 million to speed up the event of therapeutics based mostly on Akribion’s proprietary G-dase® E nucleases.
The spherical was led by CARMA FUND and RV Make investments, with investments from MP Beteiligungs GmbH, Hessen Kapital I, Bruker Make investments and Excessive-Tech Gründerfonds (HTGF).
Lukas Linnig, Co-founder and Co-CEO of Akribion, says: “Akribion is unlocking a complete new class of therapeutic potentialities with our strategy. Our proprietary G-dase® E nucleases permit very particular depletion of sure subsets of cells based mostly on the presence of a predetermined RNA sequence. Whereas we’re initially targeted on advancing groundbreaking precision oncology therapies, we consider that this strategy to programmable cell depletion might have a lot wider utility. I want to thank our traders for his or her dedication to Akribion and for his or her help in serving to us realise the potential of our know-how.”
Based in 2024, Akribion is led by Dr Michael Krohn and Lukas Linnig, Co-Founders and Co-CEO’s. Dr Adel Nada has additionally been appointed as board Chair to help the administration group. Dr Nada is a biotech government and multi-time Founder and operator. He’s at the moment a enterprise associate with Volnay Therapeutics, a cell and gene remedy investor and incubator based mostly within the US.
Akribion Therapeutics is creating a RNA-guided, nuclease-based know-how for programmable cell depletion. Its G-dase® E payload has the power to kill cells by shredding DNA and RNA, however provided that there’s a extremely particular match between the information RNA and an intracellular RNA sequence, guaranteeing that solely the focused cells are affected, leaving wholesome cells unhurt.
The G-dase® E know-how was found by Dr. Paul Scholz and his group at BRAIN Biotech AG, the specialist in biosolutions for industrial functions, throughout Michael and Lukas’s tenure there. Dr. Scholz has additionally joined Akribion as Head of Analysis and Growth.
Dr. Martin Raditsch, Normal Companion, CARMA FUND provides: “Akribion’s distinctive know-how permits the creation of a brand new class of oncology therapeutics. We’re wanting ahead to working alongside this enthusiastic group to develop new most cancers remedies with improved outcomes for sufferers on this prevalent and onerous to deal with indication.”
Initially focusing on HPV-induced Oropharyngeal Head & Neck Most cancers (OPSCC), Akribion is exploring further functions in oncology, autoimmune ailments, fibrosis, and infectious ailments.
The flexibleness and broad potential of Akribion’s know-how makes it a promising platform for numerous therapeutic areas, as by merely altering the information RNA, the know-how may be shortly tailored to focus on totally different cells, making it a lot quicker to develop new remedies in comparison with conventional strategies.
Dr. Aleksei Zeifman, Funding Director, RV Make investments, feedback: “We’re thrilled to help Akribion’s entrepreneurial group as they search to unlock the complete potential of their distinctive know-how. The excessive adaptability of the G-Dase® E platform makes it an ideal instrument to leverage our rising data of the genomic signatures of ailments throughout numerous therapeutic areas.”
Dr. Katharina Severin, Funding Supervisor at HTGF, provides: “The robust group at Akribion Therapeutics and their novel strategy to RNA-guided cell depletion pose nice potential to develop transformative therapeutic approaches. Whereas initially focusing on most cancers, there may be additionally nice promise to adapt the versatile know-how for the longer term therapy of autoimmune ailments, infectious ailments, fibrosis, and past. We’re excited to be part of their journey!”
The present financing spherical is predicted to ship in vivo Proof of Idea of Akribion’s know-how.
